FDA requires new warnings on GLP-1 drug packaging due to risk of vision loss
The U.S. regulator has required manufacturers of all GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro and Zepbound, to add information about the rare eye condition NAION, which can lead to irreversible vision loss, to their instructions. The decision is based on an analysis of 126 clinical trials involving more than 134,000 patients.
Nilufar Karimova